Test ID: BHPV
Human Papillomavirus (HPV) Detection, High-Risk Types
Method Description
Describes how the test is performed and provides a method-specific reference
The hc2 DNA (Digene) test using Hybrid Capture II technology is a nucleic acid hybridization microplate assay with signal amplification that utilizes chemiluminescent detection. Specimens containing the target DNA hybridize with a specific HPV-RNA probe cocktail. The resultant RNA:DNA hybrids are captured onto the surface of a microplate well coated with antibodies specific for RNA:DNA hybrids. Immobilized hybrids are then reacted with alkaline phosphatase conjugated antibodies specific for the RNA:DNA hybrids, and detected with a chemiluminescent substrate. Several alkaline phosphatase molecules are conjugated to each antibody. Multiple conjugated antibodies bind to each captured hybrid resulting in substantial signal amplification. As the substrate is cleaved by the bound alkaline phosphatase, light is emitted that is measured as relative light units (RLUs) on a luminometer. The intensity of the light emitted denotes the presence or absence of target DNA in the specimen. (Package insert: hc2 DNA [Digene] Specimen Collection Kit, Digene Corp., Beltsville, MD)
Day(s) and Time(s) Test Performed
Outlines the days and times the test is performed. This field reflects the day and time the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time required before the test is performed. Some tests are listed as continuously performed, which means assays are performed several times during the day.
Monday through Friday; Varies


